This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Paracetamol oral

Updated 2 Feb 2023 | Paracetamol

Presentation

Oral formulations of paracetamol.

Drugs List

  • ALTRIDEXAMOL 1g effervescent tablet
  • ANADIN PARACETAMOL tablets
  • CALPOL FAST MELTS 6+ 250mg dissolving tablets
  • MANDANOL 500mg caplets
  • MANDANOL 500mg tablets
  • PANADOL 500mg soluble tablet
  • PANADOL ACTIFAST 500mg soluble tablet
  • PANADOL ACTIFAST 500mg tablets
  • PANADOL ADVANCE 500mg tablets
  • paracetamol 1000mg tablets
  • paracetamol 1g effervescent tablets sugar-free
  • paracetamol 250mg orodispersible tablets sugar-free
  • paracetamol 500mg capsules
  • paracetamol 500mg effervescent tablet
  • paracetamol 500mg soluble tablet
  • paracetamol 500mg tablets
  • Therapeutic Indications

    Uses

    Pain - mild to moderate
    Pyrexia
    Treatment of post-operative pain

    Dosage

    A small number of manufacturers recommend a 50% dose reduction in adult patients weighing less than 50kg or in those at risk of hepatotoxicity, including Gilbert's syndrome, dehydration, chronic malnutrition and chronic alcoholism.

    Adults

    500mg to 1g every 4 to 6 hours to a maximum of 4g in 24 hours.

    650mg sachet:
    1 sachet every four hours to a maximum of 4 sachets in any 24 hours period.

    Children

    Children aged 12 to 18 years
    (See Dosage; Adult)

    Children aged 6 to 12 Years
    250mg to 500mg repeated every 4 to 6 hours as necessary, with a maximum of 4 doses in any 24 hour period.

    650mg sachet:
    Not recommended.

    Children under 6 years
    Other formulations are more appropriate.

    The following alternate dosing schedule may be suitable:

    Pain and pyrexia with discomfort
    Children aged 16 to 18 years:
    500mg to 1g every 4 to 6 hours (maximum 4 doses in 24 hours)

    Children aged 12 to 16 years:
    480mg to 750mg every 4 to 6 hours (maximum 4 doses in 24 hours)

    Children aged 10 to 12 years:
    480mg to 500mg every 4 to 6 hours when necessary. (Maximum of 4 doses in 24 hours)

    Children aged 8 to 10 years:
    360mg to 375mg every 4 to 6 hours when necessary. (Maximum of 4 doses in 24 hours)

    Children aged 6 to 8 years:
    240mg to 250mg every 4 to 6 hours when necessary. (Maximum of 4 doses in 24 hours)

    Post operative pain
    Children aged 12 to 18 years:
    1g every 4 to 6 hours (maximum 4 doses in 24 hours)

    Children aged 6 to 12 years:
    20mg/kg to 30mg/kg (maximum 1g) as a single dose then 15mg/kg to 20mg/kg every 4 to 6 hours; maximum 75mg/kg (maximum 4g daily in divided doses).

    Patients with Renal Impairment

    Alternative sources recommend a reduction to 500mg to 1g every 6 to 8 hours in patients with a GFR less than 10ml per min.
    Some manufacturers also recommend the following adjustment:
    GFR 10 to 50ml per min: 500mg every 6 hours
    GFR less than 10ml per min: 500mg every 8 hours.

    Contraindications

    Children under 6 years

    Precautions and Warnings

    Frail elderly patients
    Restricted sodium intake
    Weight below 50kg
    Alcoholism
    Dehydration
    Gilbert's syndrome
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    Hereditary fructose intolerance
    Non-cirrhotic alcoholic liver disease
    Phenylketonuria
    Severe malnutrition
    Severe renal impairment

    Sodium content of formulation may be significant
    Some formulations contain aspartame - caution in phenylketonuria
    Not all available brands are licensed for all age groups
    Not all formulations are licensed for all uses
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    Some formulations contain sucrose
    Advise patient to seek medical advice if severe skin reaction occurs
    Overdosage causes liver damage
    Seek urgent medical advice in event of overdose, even if patient feels well
    Discontinue if drug-related rash or other hypersensitivity reactions occur
    Advise that alcohol increases the chances of liver damage with paracetamol
    Consult doctor if symptoms persist or treatment is required for > 3 days
    Patients should not exceed recommended dose

    Pregnancy and Lactation

    Pregnancy

    Paracetamol is considered safe for use in pregnancy.

    Manufacturers suggest no adverse effects have been reported using this drug during pregnancy when used in the recommended dosage, but patients should follow the advice of their doctor regarding its use. Animal studies do not indicate reproductive toxicity.

    Schaefer (2015) suggests paracetamol does cross the placenta, however due to the drugs analgesic and antipyretic properties, it is the preferred drug of choice to use in pregnancy. Briggs (2015) states that paracetamol is commonly used in all stages of pregnancy and the therapeutic doses in short-term are deemed safe, while routine use should be avoided.

    Lactation

    Paracetamol is considered safe for use in breastfeeding.

    Manufacturers suggests there has been no adverse effects on the breastfed infants and newborns when used at therapeutic doses. Schaefer (2015) suggests paracetamol is the analgesic of first choice in breastfeeding. Hale and the Drugs and Lactation Database (LactMed) both suggest the potential amount of paracetamol ingested via breast milk by an infant is likely to be significantly less than the paediatric therapeutic dose.

    Side Effects

    Abdominal pain
    Abnormal vision
    Agranulocytosis
    Allergic reaction
    Anaphylactic reaction
    Anaphylactic shock
    Angioedema
    Blood dyscrasias
    Bronchospasm
    Changes in hepatic function
    Confusion
    Depression
    Diarrhoea
    Dizziness
    Erythema multiforme
    Haemolytic anaemia
    Haemorrhage
    Hallucinations
    Headache
    Hepatic disorders
    Hepatic failure
    Hepatitis
    Hepatotoxicity
    Hypoglycaemia
    Interstitial nephritis
    Jaundice
    Leucopenia
    Liver damage
    Malaise
    Nausea
    Neutropenia
    Oedema
    Pancytopenia
    Papillary necrosis
    Pruritus
    Purpura
    Pyrexia
    Rash
    Renal impairment
    Sedation
    Stevens-Johnson syndrome
    Sweating
    Thrombocytopenia
    Toxic epidermal necrolysis
    Tremor
    Urticaria
    Vertigo
    Vomiting

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: November 2016

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Abdine Cold Relief Powder sachets, Bell Sons & Co Ltd, revised July 2015.
    Summary of Product Characteristics: Altridexamol 1000mg effervescent tablets. TriOn pharma Ltd. Revised August 2017.
    Summary of Product Characteristics: Anadin Paracetamol Tablets. Pfizer Consumer Healthcare. Revised December 2015.
    Summary of Product Characteristics: Calpol Six Plus FastMelts. McNeil Ltd. Revised August 2016.
    Summary of Product Characteristics: Hedex Tablets. GlaxoSmithKline Consumer Healthcare. Revised November 2015.

    Summary of Product Characteristics: Panadol Advance 500mg Tablets. GlaxoSmithKline Consumer Healthcare. Revised August 2012.
    Summary of Product Characteristics: Paracetamol 500mg caplets. Crescent Pharma Limited. Revised November 2016.
    Summary of Product Characteristics: Paracetamol 500mg Effervescent Tablets. Accord. Revised November 2017.
    Summary of Product Characteristics: Panadol Original Tablets. GlaxoSmithKline Consumer Healthcare. Revised August 2014.
    Summary of Product Characteristics: Paracetamol Tablets BP 500mg. Actavis UK Ltd. Revised September 2014.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
    Paracetamol Last revised: 31 October 2018
    Last accessed: 11 January 2018

    NICE Evidence Services Available at: www.nice.org.uk Last accessed: 11 January 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.